

がん対策推進総合研究事業事前評価委員名簿

(○ : 委員長)

石塚 直樹	京都大学大学院医学系研究科附属医療 DX 教育研究センター 特定教授
専門分野 生物統計	
Randomized controlled trial of artificial intelligence diagnostic system in clinical practice to detect esophageal squamous cell carcinoma. Nakao E, Yoshio T, Kato Y, Namikawa K, Tokai Y, Yoshimizu S, Horiuchi Y, Ishiyama A, Hirasawa T, Kurihara N, <u>Ishizuka N</u> , Ishihara R, Tada T, Fujisaki J. Endoscopy. 2024 Sep 24. doi: 10.1055/a-2421-3194. Online ahead of print.	
Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study. Takahashi D, Katai H, Takashima A, Izawa N, <u>Ishizuka N</u> , Ohashi M, Mikami S, Wakatsuki T, Nakayama I, Chin K, Ida S, Kumagai K, Nunobe S, Iwasa S, Shoji H, Wada T, Doi A, Yoshikawa T, Sano T, Boku N, Yamaguchi K. Gastric Cancer. 2023 Jul;26(4):614-625.	
Oncologic Outcomes of Laparoscopic Radical Hysterectomy Using the No-Look No-Touch Technique for Early Stage Cervical Cancer: A Propensity Score-Adjusted Analysis. Fusegi A, Kanao H, Ishizuka N, Nomura H, Tanaka Y, Omi M, Aoki Y, Kurita T, Yunokawa M, Omatsu K, Matsuo K, Miyasaka N. Cancers (Basel). 2021 Dec 3;13(23):6097.	

小原 明	東邦大学医学部 名誉教授
小児血液学	
〈研究論文〉共著 Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients. Hangai M, Kawaguchi T, Takagi M, Matsuo K, Ohara A. 他 61 名 Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.282914.	
〈著書〉分担執筆 遺伝性骨髓不全症診療ガイドライン 2023 日本小児血液・がん学会（編） 診断と治療社 2023 ISBN978-4-7878-2559-9	

上別府 圭子	国際医療福祉大学大学院・看護学分野長/教授
家族看護学・小児がん・長期フォローアップ	
〈研究論文〉 Rei Oshiro, Masahiko Tanabe, Keiichiro Tada, Junko Takei, Hideko Yamauchi, Youko Warita, Kiyoko Kamibeppu. <u>Post-traumatic growth and cancer-related communication among adolescents having mothers with breast cancer</u> . Supportive Care in Cancer 31(7) ; 446, 2023.	
〈研究論文〉 Miki Morishita-Kawahara, Kazuhiko Koike, Takuya Kawahara, Kiyoko Kamibeppu. <u>The relationship between satisfaction with care and quality of life among family caregivers of patients living with terminal cancer in general wards: a cross-sectional study</u> . International Journal of Palliative Nursing 28(12) ; 575-582, 2022.	
〈教科書〉 上別府圭子（責任編者）；日本小児がん看護学会小児がん看護テキスト作成ワーキンググループ（編）. <u>小児がん看護テキストブック</u> . 杏林書院, 2023. (ISBN: 9784764405424)	

小松本 悟	足利赤十字病院 名誉院長
脳神経内科、病院管理学、病院経営マネジメント	
小松本悟／いまさら聞けない病院経営～明日からの病院経営改善に向けて～／経営書院／2019年2月	
小松本悟／いまさら聞けない病院経営～施設基準の重要性と適時調査・個別指導の実際～／経営書院／2021年2月	
小松本悟／病院建築の現在と未来を語る（巻末付録）／編著 近藤彰宏、大宇昌利／日本医療企画／2021年3月31日発行	

佐谷 秀行	藤田医科大学がん医療研究センター・センター長
腫瘍生物学	
<研究論文例>	
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H and <u>Saya H</u> : CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. <i>Cancer Cell</i> 19: 387-400, 2011	
<研究論文例>	
Marumoto T, Zhang D and <u>Saya H</u> : Aurora A – A guardian of poles. <i>Nat Rev Cancer</i> 5:42-50, 2005	
<研究論文例>	
Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K and <u>Saya H</u> : Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. <i>Cell</i> 114: 585-598, 2003	

永田 知里	岐阜大学大学院医学系研究科 疫学・予防医学・教授
専門分野 疫学、予防医学	
Wada K, Hattori A, Maruyama Y, Mori T, Sugino M, Nakashima Y, Yamakawa M, Yamamoto M, Hori A, Seishima M, Tanabashi S, Matsushita S, Nagata C. Dietary melatonin and liver cancer incidence in Japan: From the Takayama study. <i>Cancer Sci.</i> 2024 May;115(5):1688–1694.	
Nagata C. Soy intake and chronic disease risk: findings from prospective cohort studies in Japan. <i>Eur J Clin Nutr.</i> 2020 Jun;75(6):890–901.	
Nagata C, Wada K, Sahashi Y, Tamura T, Konishi K, Goto Y, Yamakawa M, Koda S, Mizuta F, Uji T, Nakamura K, Tsuji M, Nagai H, Itakura N, Harada K, Takahara O, Yamanaka H. The Hekinan Children's Study: Design and Profile of Participants at Baseline <i>J Epidemiol.</i> 2019 Jul;29(7):272–277.	

馬場 秀夫	国立大学法人熊本大学大学院生命科学研究部消化器外科学 教授
外科学一般、消化器外科学、腫瘍学	
<p>Imai K, Baba H: Initially unresectable colorectal liver metastases: the best therapeutic regimens. <i>Lancet Oncol.</i> 2023 Jun 14;S1470-2045(23)00271-1. doi: 10.1016/S1470-2045(23)00271-1.</p>	
<p>Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nat Med</i> 24:968-977, 2018</p>	
<p>Baba H, Yamada Y, Takahashi D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K: S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> 2:e000135, 2017</p>	

眞島 喜幸	NPO 法人パンキャンジャパン 理事長
キャンサー アドボカシー、医療政策分析	
Neuro-Oncology Advances, Volume 4, Issue Supplement_3, December 2022, Page iii19, https://doi.org/10.1093/noajnl/vdac167.072	
NQPC-8 UNMET NEEDS OF CANCER PATIENTS SURVEY 2022: INTERIM ANALYSIS RESULTS	
Int J Cancer. 2020 Mar; 146(5):1316–1323 Published online 2019 Oct 25. doi: 10.1002/ijc.32678 Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates, and NET health care professionals.	
Japanese Journal of Clinical Oncology, Volume 50, Issue 11, November 2020, Pages 1333–1341, https://doi.org/10.1093/jjco/hyaa119 Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer	

○	南 博信 教授	神戸大学大学院医学研究科腫瘍・血液内科学 教授
腫瘍内科学		
Guidelines for clinical evaluation of anti-cancer drugs. <u>Minami H</u> , Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira S, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K. Cancer Sci 112;2563–2577, 2021		
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. Hayashi H, Takiguchi y, <u>Minami H</u> , Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. JAMA Oncol 15: 6(12) :1–9, 2020		
Asciminib in tyrosine kinase inhibitor-resistant and -intolerant chronic myeloid leukemia. Hughes TP, Mauro MJ, Cortes JE, <u>Minami H</u> , Rea D, DeAngelo DJ, Breccia M, Goh Y-T, Talpaz, M, Hochhaus A, le Coutre P, Ottmann O, Heinrich, MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon F-X, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan R, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim D-W. New Engl J Med 381: 2315–2326, 2019		